Editorial
Volume 8 Issue 2
Samorindo Peci*
January 07, 2026
DOI : 10.56831/PSMPH-08-269
Abstract
Chronic inflammatory and immune-mediated conditions are frequently characterized by a persistent imbalance between pro-inflammatory cytokines and regulatory immune pathways, often refractory to conventional targeted therapies. While monoclonal antibody treatments offer highly specific molecular inhibition, their single-target approach may not adequately address the complexity of dysregulated cytokine networks. This editorial discusses the biological rationale and emerging clinical evidence supporting autologous cytokine-based monoclonal therapies as a systemic immunoregulatory strategy. Drawing on over a decade of clinical experience and published case series, the modulation of endogenous cytokine profiles—particularly through regulatory mediators such as interleukin-10 (IL-10)—is examined as a means of restoring immune homeostasis rather than inducing unidirectional suppression. The relevance of this approach is explored in chronic inflammatory, autoimmune, and post-oncological immune-dysregulation settings, where conventional therapies may fail to provide sustained clinical benefit. By leveraging patient-derived immunoregulatory mechanisms, autologous cytokine-based monoclonal therapies represent a biologically coherent and potentially cost-effective adjunct or alternative to existing immunomodulatory strategies, warranting further scientific discussion and systematic investigation.
Keywords: Autologous cytokine therapy; Immunoregulation; Cytokine network modulation Interleukin-10 (IL-10); Chronic inflammatory diseases
References